Y. Peter Li is the exCo-founder, Chairman, President, and CEO at Turning Point Therapeutics. Y. Peter Li, Ph.D., M.B.A. has extensive experience in biotech management. He served as Executive Vice President at Epitomics, Inc., a leading antibody technology company specializing in rabbit monoclonal antibody development for reagent, diagnostics, and therapeutics (acquired by Abcam, plc in March 2012). He spent more than 9 years at the company, initially as Vice President of Life Sciences, then Senior Vice President, and Executive Vice President. At Epitomics, Peter successfully built its reagent business from concept to sizable operations in both U.S. (35 FTEs) and China (165 FTEs). He oversaw all aspects of this business line which included R&D, manufacturing, QC, marketing/sales, customer services, and oversea distributor relationship. Peter also made important contributions to corporate strategy and execution at Epitomics. Prior to Epitomics, Peter was Vice President at Kenson Ventures, LLC. He evaluated business plans and consulted for biotech startups on business strategies, operations, marketing and business development. He has served as members of Board of Directors and observers to the Board for biotech companies.